Immatics NV (IMTX)
10.94
+0.13
(+1.20%)
USD |
NASDAQ |
May 17, 16:00
10.94
0.00 (0.00%)
After-Hours: 20:00
Immatics SG&A Expense (Quarterly): 12.65M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.65M |
| December 31, 2023 | 11.17M |
| September 30, 2023 | 9.670M |
| June 30, 2023 | 10.20M |
| March 31, 2023 | 10.30M |
| December 31, 2022 | 9.960M |
| September 30, 2022 | 8.484M |
| June 30, 2022 | 9.25M |
| March 31, 2022 | 10.41M |
| December 31, 2021 | 10.11M |
| Date | Value |
|---|---|
| September 30, 2021 | 9.746M |
| June 30, 2021 | 9.968M |
| March 31, 2021 | 10.16M |
| December 31, 2020 | 10.37M |
| September 30, 2020 | 10.78M |
| June 30, 2020 | 11.10M |
| March 31, 2020 | 6.838M |
| December 31, 2019 | 5.104M |
| September 30, 2019 | 3.079M |
| June 30, 2019 | 2.364M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.364M
Minimum
Jun 2019
12.65M
Maximum
Mar 2024
9.085M
Average
10.04M
Median
SG&A Expense (Quarterly) Benchmarks
| MorphoSys AG | -9.867M |
| Affimed NV | 6.642M |
| InflaRx NV | 5.473M |
| BioNTech SE | 144.03M |
| CureVac NV | 23.35M |